Search Results

Tempest Therapeutics, Inc. announced that collaborators at the Beth Israel Deaconess Medical Center at Havard Medical School will present a poster with preclinical data supporting the advancement of TPST-1120 as a potential treatment for renal cell carcinoma at the American Association for Cancer Research Annual Meeting taking place April 5-10, 2024 in San Diego, CA.

Tempest Therapeutics, Inc. (Nasdaq: TPST) today announced that collaborators at the Beth Israel Deaconess Medical Center (BIDMC) at Havard Medical presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting demonstrating that TPST-1120 reduces kidney cancer (RCC) growth as a monotherapy, while also showing increased inhibition when combined with frontline chemotherapy and immunotherapy.

The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative has awarded $75,000 to David E. Avigan, MD, of Beth Israel Deaconess Medical Center and Harvard Medical School for the development of a personalized dendritic cell/organoid-based vaccine for the treatment of gastric cancer.

Alpha Tau Medical Ltd. announced that a patient with advanced inoperable pancreatic cancer has been treated in a clinical trial at Hadassah Medical Center in Jerusalem, Israel.

QuantalX Neuroscience, a leading medical device company specializing in Brain Health diagnosis, is thrilled to announce a significant partnership with The Sheba Longevity Center, part of the prestigious Sheba Medical Center, Israel.